Кения - английский - Pharmacy and Poisons Board

macleods pharmaceuticals limited 304, atlanta arcade, marol church road, andheri - rifampicin isoniazid - dispersible tablet - rifampicin bp 75 mg isoniazid bp 50 mg - antimycobacterials: combinations of drugs for

Канада - английский - Health Canada

sanofi-aventis canada inc - rifampin - capsule - 150mg - rifampin 150mg - antituberculosis agents

Канада - английский - Health Canada

sanofi-aventis canada inc - rifampin - capsule - 300mg - rifampin 300mg - antituberculosis agents

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 20 mg/ml - oral liquid - excipient ingredients: agar; sucrose; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; saccharin; polysorbate 80; diethanolamine; purified water; sodium metabisulfite; fragrance (perfume) - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Израиль - английский - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rifabutin - capsules - rifabutin 150 mg - rifabutin - rifabutin - for the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. for the treatment of infections caused by mac or other atypical mycobacteria where there is evidence of resistant bacteria as above. for the treatment of infections caused by mac or other atypical mycobacteria in aids patients in all cases not subject to the above restrictions. for prevention of mac infections in aids patients whose cd4 counts lower or eqval to 200/mm3

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin -

Канада - английский - Health Canada

sanofi-aventis canada inc - rifampin; isoniazid; pyrazinamide - tablet - 120mg; 50mg; 300mg - rifampin 120mg; isoniazid 50mg; pyrazinamide 300mg - antituberculosis agents

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - rifampicin - oral capsule - 300mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - rifampicin - oral capsule - 300mg

Соединенные Штаты - английский - NLM (National Library of Medicine)

rebel distributors corp - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin capsule and the patient is not responding to therapy, the drug regimen should be modified. rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tuberculosis, the american t